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Abstract
Human cells respond to DNA damage with an acute and transient burst in production of
poly(ADP-ribose), a posttranslational modification that expedites damage repair and plays a
pivotal role in cell fate decisions. Poly(ADP-ribose) polymerases (PARPs) and glycohydrolase
(PARG) are the key set of enzymes that orchestrate the rise and fall in cellular levels of
poly(ADP-ribose). In this perspective, we focus on recent structural and mechanistic insights into
the enzymes involved in poly(ADP-ribose) production and turnover, and we highlight important
questions that remain to be answered.
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Introduction
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Cells respond instantaneously to DNA damage with posttranslational modifications of
proteins that repair DNA damage, alter gene expression, or control passage through the cell
cycle. The covalent modification of these proteins induces a dynamic network of proteinprotein interactions and regulates enzymatic activities, broadly changing cellular physiology
and serving to integrate myriad responses to DNA damage that dictate outcomes for DNA
repair, cell survival, and responses to chemotherapy. One of the most prodigious
posttranslational modifications caused by DNA damage is the poly-(ADP-ribosylation) of
proteins, catalyzed by members of the poly-(ADP-ribose) polymerase (PARP) superfamily
of NAD+ dependent ADP-ribosyltransferases [1]. Poly-(ADP-ribose) (PAR) is a large,
negatively-charged and branched polymer that can exceed the mass of the unmodified
protein. PARylation creates binding sites for PAR-specific binding proteins [2,3] and
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changes the electrostatic properties of the modified protein, with the notable capacity to
change DNA binding properties of enzymes, histones, and structural proteins [4]. PARP-1
itself is the target of most of the poly-(ADP-ribosylation) (PARylation) occurring in
response to DNA damage. Automodification of PARP-1 increases its association with a
variety of repair and signaling proteins that are recruited to sites of DNA damage by
PARP-1 activity [3,5]. In turn, some of these proteins are PARylated by PARP-1.

Author Manuscript

PARP enzymes responding to damage can consume substantial amounts of cellular NAD+
within minutes, changing a cell’s metabolic status while modifying vast numbers of
proteins, many of which have been only recently identified by proteomic surveys [6,7]. For
most of these proteins, the effects of PARylation remain to be functionally characterized.
These studies are complicated by the fact that PAR modifications turn over rapidly due to
the activity of poly-(ADP-ribose) glycohydrolase (PARG) and mono-(ADP-ribose)
glycohydrolases (MARGs) [8,9]. Both the synthesis and turnover of poly-(ADP-ribose)
appear to be important for normal responses to DNA damage. In this short perspective, we
will review the recent literature on the structures and functions of DNA damage-dependent
PARPs and PARG, and then speculate about how these activities may be tied
mechanistically to various disease processes and the resulting opportunities for therapeutic
intervention.

Structure and mechanism of DNA damage-dependent PARPs
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Three members of the PARP superfamily are catalytically activated through interaction with
DNA damage: PARP-1, PARP-2, and PARP-3. PARP involvement in the cellular response
to DNA damage has long been appreciated and continues to actively develop [10,11]. A
general model that has collectively emerged indicates that the DNA-damage dependent
PARPs act early in the process of damage detection, which promptly results in PARP
catalytic activation and a burst of PAR production. PARP presence and activity at the
damage site then can contribute to the efficiency of the repair process and the repair pathway
choice. A key role of the DNA-damage dependent PARPs and the PAR modification they
produce is to recruit repair factors to the site of damage. Several motifs and domains have
been identified in repair proteins that mediate the interaction with PAR and the recruitment
to sites of PAR synthesis [12,13]. In addition to PAR serving as a recruiting platform, PAR
modification of repair and chromatin-associated factors in the vicinity of a damage site is
expected to change the catalytic properties of targeted proteins, and the local structure of
chromatin [10]. However, detailed insights into PAR-mediated regulation of protein
function are lacking in general. And although a general model for PARP contribution to the
DNA damage response has formed, the molecular details of PARP involvement are not
clearly established, which has limited our understanding of PARP’s contribution to specific
steps of repair, and the contribution of different PARPs to repair pathway choice. Over
recent years, structural and biochemical studies have provided key insights into the early
stages of PARP-1 involvement in DNA repair: the detection of DNA damage, and the
allosteric coupling of damage detection to acute levels of PAR production. Here we will
provide an overview of these important insights into PARP-1 mechanism, and we will
indicate some of the key questions that remain to be answered.
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The DNA-damage dependent PARPs have similar catalytic domain structures, but they
differ somewhat in the domains that contact DNA damage (Figure 2)[13]. In the catalytic
domain, they share a conserved structural feature known as the helical domain (HD) [14]
(also referred to as the PARP regulatory domain – PRD). The HD is only found in the DNAdamage dependent PARPs, and it plays an important role in regulating PARP catalytic
activity, as described later. The HD is adjacent to the ADP-ribosyl transferase (ART) fold,
which is common to all PARP family members. The ART contains the binding site for
NAD+, which donates ADP-ribose, and a second binding site for an ADP-ribose unit, which
accepts the next ADP-ribose during the PAR extension reaction that can result in both linear
and branched polymers [15,16](Figure 2). Detailed structural views of PAR biosynthesis
(NAD+ binding, initiation on target protein, polymer extension) have not been obtained, thus
our complete understanding of PAR synthesis is limited. The NAD+ binding sites for the
DNA-damage dependent PARPs are similar and have the conserved His-Tyr-Glu (HYE)
amino acids that define catalytically active PARP members capable of forming PAR (as
opposed to mono-ADP-ribose)[17,18]. The acceptor binding sites vary between PARP-1,
PARP-2, and PARP-3 and this is likely to influence the type of polymer formed (e.g.
polymer length, number of branch points). For example, PARP-3 has an Arg residue in the
acceptor site where PARP-1 and PARP-2 have a Met residue, which is expected to
contribute to the binding pocket for the adenosine base of an acceptor ADP-ribose
modification [16]. Presumably this change in sequence perturbs the binding site and
contributes to the smaller size of polymer produced by PARP-3 [18]. It is not understood
how the differences in the structure of PAR produced might differentially influence
downstream signaling to repair pathways, and it will be important to resolve this issue.

Mechanism of PARP-1 activation
Author Manuscript
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Outside of the catalytic domain, the DNA-damage dependent PARPs also have in common a
Trp-Gly-Arg (WGR) domain that is essential to damage-dependent activation, and is the
most defining feature of the DNA-damage dependent PARPs. A crystal structure that
contained the essential domains of PARP-1 in complex with DNA damage provided the first
views of the WGR domain contacts with DNA (Figure 2). The structure indicated that
conserved regions of the WGR make sequence-independent contacts with the DNA
backbone near the 5′ terminus [19]. The importance of these contact residues to catalytic
activation was confirmed through mutagenesis. Although their are no structures for PARP-2
and PARP-3 in complex with DNA damage, it is interesting to note that their activation
levels are sensitive to modifications to the 5′ terminus of the DNA, such as phosphorylation
[20], suggesting that their WGR domains have specialized interactions with the 5′ terminus.
PARP-1 in contrast is relatively insensitive to the detailed composition of the break site,
consistent with the PARP-1 complex structure in which the 5′ terminus is not directly
contacted [19]. The biochemical results for PARP-2 and PARP-3 suggest that they are most
potently activated at certain stages of the repair process, for example, when a DNA break
has been processed to the point of containing a 5′ phosphorylated nick that is competent for
DNA ligation [20]. Indeed, the efficiency of recovery from a DNA double-strand break
depends on PARP-3, which is proposed to aid recruitment of the DNA ligation complex that
completes the NHEJ repair pathway [21]. Hence, there are likely to be important variations
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in the mechanism of activation for each of the DNA-damage dependent PARPs that
contribute to their specialization toward distinct repair pathways, and the stage at which they
act within a given repair pathway. Further structural and biochemical studies will help to
further define the specifics of the particular PARP involvement in the DNA repair response.

Author Manuscript

In addition to engaging DNA damage, the WGR domain makes important contacts with the
HD, and thus physically couples damage detection to the catalytic domain, which does not
bind DNA [19](Figure 2). These WGR contacts induce destabilizing structural changes in
the HD that are associated with PARP-1 activation, and they are suggested to involve a
change in protein dynamics [22]. However, the precise role of HD structural transitions and
their potential impact on the ART are not clear and require further investigation.
Understanding these structural changes is likely to be relevant to the mode of PARP
inhibitor binding, since all clinical PARP inhibitors interact with the ART. WGR–HD
contacts and their importance to activation are conserved in PARP-2 and PARP-3, as well as
the destabilizing changes in HD, thus indicating that the allosteric coupling of damage
detection to catalytic activation will proceed through similar mechanisms for the DNA
damage-dependent PARPs [20]. In contrast, the DNA damage binding interfaces of
PARP-1, PARP-2, and PARP-3 are likely to have significant variations based on their
differences in domain composition. It will be important to understand these differences in
greater detail, as it will help to clarify the specific roles that each DNA damage-dependent
PARP performs in repair.
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Outside of the WGR domain, there are other regulatory domains that contribute to the
activation of the DNA-damage dependent PARPs. Most notably, PARP-1 has three Nterminal zinc-binding domains that contribute to DNA binding and catalytic activation in
different ways (Figure 2). The crystal structure of PARP-1 essential domains in complex
with a DNA double-strand break illustrated how the first zinc finger (Zn1 or F1) and the
third zinc finger (Zn3 or F3) collaborate with the WGR to bind DNA damage (Figure 2).
Each of these three domains is strictly required for PARP-1 catalytic activation by DNA,
and the required domain-domain interfaces formed between them when engaging DNA
represent novel targets for selective inactivation of PARP-1, since the zinc finger domains
are unique regulatory domains only found in PARP-1 [23,24]. Zn1 plays a central role in
damage detection by forming contacts with the nucleotide bases that are exposed at the
DNA double strand break. This mode of interaction is consistent with earlier crystal
structures of Zn1 and Zn2, each individually bound to a double strand break [25]. In all
cases, Zn1 and Zn2 do not contact the 5′ and 3′ terminal ends of the break, and thus can
allow extensions of these ends that are present in different types of DNA damage (e.g. single
strand breaks). Thus, the Zn1 and Zn2 mode of engagement allows them to engage a variety
of damage DNA structures. A different mode of DNA interaction was observed in a crystal
structure of the Zn1-Zn2 fragment of PARP-1 in complex with a double-strand break
bearing a single nucleotide overhang [26]. Although the Zn2-DNA contacts matched those
seen in previous structures, the polarity of the Zn1 domain with respect to the DNA
backbone was reversed. The reversed polarity was surprising given the structural homology
and sequence identity between Zn1 and Zn2. Moreover, the positioning of the Zn1 in this
complex sterically prevents the essential WGR domain from binding to the DNA; thus it is
hard to envision how this binding mode could lead to PARP-1 activation. Lastly, the relative
DNA Repair (Amst). Author manuscript; available in PMC 2016 August 01.
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positioning of the Zn1 and Zn2 domains necessitates that they originate from separate
polypeptides, which is at odds with a number of recent biophysical studies indicating that
PARP-1 interacts as a monomer with DNA [19,27–30]. Thus, the relevance of the reversed
binding mode of Zn1 requires further investigation. Indeed, additional structural studies are
needed to help clarify this discrepancy, and to fully understand how PARP-1 engages
various types of DNA damage. Furthermore, it will be important to decipher how PARP
interaction with DNA damage is different from its interaction with undamaged DNA, and
the functional consequences of these differences [31,32]. Perhaps most notably, the
structural basis for PARP-1 engaging a single-strand break is a clear gap in our
understanding of PARP-1 function as a “nick” sensor. PARP-2 and PARP-3 lack the
extensive regulatory domains seen in PARP-1, but still have extensions N-terminal to the
WGR that at least play a role in DNA binding and activation [20]; however, there are limited
structural and mechanistic insights into their N-terminal regions and how they might
specialize the function of PARP-2 and PARP-3.
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Despite the recent advances in understanding DNA damage detection and catalytic
activation, there are critical deficiencies in our understanding of how PARP modification
can influence protein structure and activity. Perhaps the most prominent deficiency is our
understanding of PARP-1 automodification. PARP-1 automodification has two somewhat
opposing outcomes: recruitment of repair factors to PARP-1 at sites of damage, and release
of PARP-1 from the site of damage. It is unclear how this transition occurs. There has been
much recent progress in the identification of PARP automodification sites using mass
spectrometry [33–37]. However, there is still much to learn in terms of the functional
consequences of modification at a given site, and whether modification at different residues
could lead to different outcomes (e.g. PARP-1 mediated recruitment versus PARP-1
release). Understanding the mechanism of PARP-1 release from DNA damage has relevance
to the effects of certain clinical PARP inhibitors that prevent the release mechanism to
varying degrees and “trap” PARP molecules on DNA damage [38,39]. Understanding
PARG involvement in reversing the PAR modification and regulating PARP function will
be equally important in understanding both biologically and medically relevant questions.

Turnover of poly-(ADP-ribose) is required for normal responses to DNA
damage

Author Manuscript

The enzymatic synthesis of poly-(ADP-ribose) and its degradation are commensurately
important for normal responses to DNA damage. In mammals, the enzyme poly-(ADPribose) glycohydrolase (PARG) is the main activity that removes poly-(ADP-ribose) from
proteins by cleaving ribose-ribose bonds [8]. PARG is an abundant enzyme that degrades
PAR by a combination of endo- and exo- glycohydrolase activity, removing most of the
PAR polymer but leaving a single ADP-ribose attached to the protein. The remaining ADPribosyl modification can be removed by one of several recently identified mono-(ADPribose) glycohydrolases [33,40].
Genetic disruption of the PARG gene causes embryonic lethality, and decreased PARG
activity sensitizes cells to a spectrum of DNA damaging agents resembling that caused by
genetic knockdown of PARP-1 expression or pharmacologic inhibition of PARP activity
DNA Repair (Amst). Author manuscript; available in PMC 2016 August 01.
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[41]. For example, BRCA2-deficient cells that are markedly sensitive to PARP inhibitors are
also hypersensitive to PARG inhibition by the nonselective inhibitor, gallotannin [42]. These
observations suggest that returning transiently PARylated proteins to their unmodified state
is cytoprotective, and additionally, that the accompanying metabolic conversion of NAD+
≫ poly-(ADP-ribose) ≫ ADP-ribose may be important for recovery from damage, as
discussed below.

Structure and mechanism of PARG
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The crystal structure of a bacterial PARG from Thermomonospora curvata [43] revealed an
evolutionarily conserved fold that is representative of the core structures of mammalian and
Tetrahymena PARG enzymes [44–47] (Figure 3A). The catalytic domains of these enzymes
share a mixed α, β architecture resembling a Rossman fold, originally termed a macro
domain in the transcriptionally repressive histone protein variant, macro-H2A [48]. The
macro domain fold binds to ADP-ribose monomers and polymers [49], and it is found in
mono- and poly-(ADP-ribose) glycohydrolases, PAR binding histones, and other enzymes.
The macro domain of PARG has a prominent substrate binding groove that engages ADPribose, or the tight-binding analog ADP (hydroxymethyl)pyrrolidinediol (ADP-HPD), in the
crystal structures. The active site of T. curvata PARG is well suited for binding to the
terminal ADP-ribose of a PAR polymer, consistent with the exo-glycohydrolase activity of
this enzyme [43]. The C-terminal helix of T. curvata PARG walls off one end of the ADPribose binding site, creating a pocket that can accept the terminal ADP-ribose and would
interfere with binding to internal sites of the PAR polymer [43]. In contrast, the ADP-ribose
binding site of mammalian PARGs is open on both ends, enabling a PAR polymer to be
positioned for endo- cleavage at internal ribose-ribose bonds [44,46]. Endo- cleavage of
PAR chains underlies a proposed mechanism for PARP-dependent cell death, with the
generation of oligo-PAR chains that trigger mitochondrial release of the death factor,
apoptosis inducing factor (AIF) [50,51].

Author Manuscript

The catalytic schemes proposed for PARG are based on the locations of conserved active
site residues and the mutational studies supporting their functional importance
[43,44,46,52]. A lone glutamic acid (E756 in human PARG) is positioned where it can
function as a general acid and a general base, to facilitate the exchange of the [n+1] poly(ADP-ribose) leaving group for a water-derived hydroxyl. Additional contacts with the 2″OH, 3″-OH, or 5″O of the ribose” sugar may enhance the reactivity of a oxocarbenium-like
intermediate for nucleophilic attack by water. Structures of PARG bound to ADP-ribose and
the dinucleotide (ADP-ribose)2 indicate that the ribose” ring could interact with the side
chain carboxylates of nearby acidic residues or with a nonbridging oxygen from the αphosphorous of the terminal [n] ADP-ribose group, in a substrate-assisted mode of catalysis.
Substrate-assisted catalysis is well documented in other glycosidases [53,54] and is a
plausible mechanism for PARG, based on the structural data. Either of two bound waters
observed in the crystal structure of human PARG could function as the attacking
nucleophile, and their different positions with respect to the anomeric carbon would support
either a retaining or inverting mechanism. Additional experimental work on the catalytic
mechanism of PARG may lead to a better understanding of the nearly 1000-fold
enhancement of ADP-HPD binding affinity in comparison to ADP-ribose binding [55], and
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will aid in the rational development of drug-like small molecule inhibitors directed at the
active site of human PARG.

PAR degradation and DNA repair
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During the DNA damage response, PARG activity reverses the automodification of DNA
bound PARP-1, concurrent with poly-ubiquitinylation of PARP-1 by the E3 ligase CHFR,
and subsequent proteasomal degradation of PARP-1 [56]. Decreased activity of either
CHFR or PARG delays repair and causes hypersensitivity to DNA damage [41,57–59],
indicating that transient PARylation of PARP-1 and the subsequent removal of PARP-1
from DNA strongly contribute to the repair of DNA strand breaks. How PARP-1 turnover
contributes to DNA repair is unknown, yet it is relevant to the therapeutic uses and
outcomes of PARP inhibitors to treat breast and ovarian cancers, or for the development of
therapeutically useful inhibitors of PARG. The regulation of chromatin-bound PARP-1 at
sites of DNA damage may enable the remodeling of DNA repair complexes and/or the DNA
substrate in order to complete the repair. CHFR-dependent removal of PARP-1 may
promote remodeling of repair intermediates and further curtail PARP-1 enzymatic activity to
preserve cellular NAD+ levels [56]. The exact role of PARG in this process remains to be
investigated. The functionally relevant target(s) of PARG activity during DNA strand break
repair may be proteins other than PARP-1, such as histones or the DNA repair scaffolding
protein XRCC1, which are modified at sites of PARP-1 activity on chromatin. PARG
activity also generates biologically active metabolites that may alter the fate of cells
experiencing high level DNA damage, as discussed below.

PAR turnover and cell death
Author Manuscript
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PAR oligomers and ADP-ribose are the products of PARG endo- and exo- glycohydrolase
activities, respectively. The cellular levels of these metabolites could increase substantially
when PARP-1 is hyperactive because PAR is rapidly degraded by PARG [12]. Oligo-PAR
has been posited as a signaling molecule that triggers a caspase-independent pathway of
programmed cell death, termed necroptosis or parthanatos [50,51]. Cell death resulting from
PARP-1 hyperactivation is typically associated with the proteolytic cleavage of apoptosis
inducing factor (AIF) and its translocation from mitochondria to the nucleus [60]. Under
some experimental conditions, AIF translocation and cell death are observed in the absence
of caspase activity, and thus, independent of the intrinsic pathway of apoptosis. Cleavage
and translocation of AIF are hallmarks of the pathway and the mechanisms that trigger these
events are under active investigation [61–63]. It has been proposed that oligo-PAR chains
produced by the combined activities of nuclear PARP-1 and PARG could diffuse out of the
nucleus and interact with the mitochondrial outer membrane to trigger AIF release [51]. A
substantial body of compelling evidence for this mechanism has been reported, although
there are some important details remaining to be clarified. AIF is normally associated with
the inner mitochondrial membrane, so the reported localization of AIF to the outer surface of
isolated mitochondria [64] is surprising and will require additional verification.
Furthermore, purified PARG is predominately an exo-glycohydrolase, producing ADPribose from posttranslationally modified PARP-1 and from purified oligo-PAR chains. It is
unclear whether oligo-PAR chains would be spared from further digestion by cytoplasmic
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PARG long enough to function as signaling molecules. A conceivable remedy would be an
oligo-PAR binding protein functioning as a chaperone during transit of PAR chains from the
nucleus to mitochondria. In support of the proposed mechanism, overexpression of a
cytoplasmic isoform of PARG blocks the nuclear translocation of AIF during PARP
hyperactivation, consistent with an important role for oligo-PAR chains in the necroptosis
pathway [50]. Determining the exact role of oligo-PAR in the necroptosis cell death
pathway will have important implications for the pathogenesis and possible treatment of
disease states related to neuronal excitotoxicity and ischemia-reperfusion injury [63].

Author Manuscript

The end product of PAR hydrolysis, ADP-ribose, could also signal DNA damage and
contribute to PARP-dependent cell death. The NAD+ metabolite 2′, 3′-cyclic ADP-ribose
(cADP-ribose) triggers mobilization of intracellular Ca2+ stores, whereas ADP-ribose and
cADP-ribose both stimulate the gating activity of a nonselective plasmalemmal Ca2+
channel, the transient receptor potential melastatin 2 (TRPM2) channel [65]. TRPM2
channel activity contributes to the pathogenesis of ischemia-reperfusion (IR) injury, a
pathological condition associated with high levels of PARP-1 activation [66,67]. A knockdown of TRPM2 expression decreases cell death and tissue injury caused by IR, as does
pharmacological inhibition of PARP-1. These observations provide circumstantial evidence
that TRPM2 channel activity may contribute to PARP-dependent cell death [68]. The
TRPM2 protein contains a C-terminal gating domain that is homologous to NUDT9, an
ADP-ribose pyrophosphatase [69,70]. In whole cell and patch clamp experiments, the
application of ADP-ribose to the intracellular surface of the membrane causes an immediate
stimulation of TRPM2 channel activity, which is further enhanced by low levels of Ca2+.
These results argue for a direct role of ADP-ribose as a positive effector of TRPM2
mediated calcium fluxes.
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TRPM2 channel activity and increasing intracellular Ca2+ could promote AIF-dependent
cell death in several ways. Elevated intracellular Ca2+ activates the cysteine protease
calpain-μ, which cleaves AIF’s N-terminal membrane anchor to release AIF into the
mitochondrial intermembrane space [71]. Egress of cleaved AIF from the mitochondrion
requires permeabilization of the outer mitochondrial membrane, and a number of
mechanisms for this have been proposed [60]. In particular, dysregulation of intracellular
Ca2+ levels causes mitochondrial depolarization by promoting the mitochondrial
permeability transition, which may facilitate the release of AIF into the cytoplasm.

Therapeutic interventions directed at poly (ADP-ribose) metabolism
Author Manuscript

A growing number of PARP inhibitors in clinical trials show promise for the treatment of
cancer, although the exact mechanism(s) of their tumor-selective killing effects remain
enigmatic [72]. Inhibitors targeting the active site of PARP-1 suffer from dose limiting
toxicity, which may result from inadequate binding specificity and off target effects on other
PARP family members. As an alternative strategy, inhibitors blocking the DNA-dependent,
allosteric activation of PARP-1 enzymatic activity may be more selective for PARP-1 and
therefore a safer therapeutic strategy [24]. Additionally, inhibitors of the poly (ADP-ribose)
glycohydrolase PARG may also prove useful for killing repair-deficient tumors, and
possibly with fewer side effects, since PARG is monogenic and without paralogs [42,73].
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Pharmacological agents targeting poly (ADP-ribose) metabolism may have other therapeutic
applications as well, such as the treatment of stroke and other neurological injuries, or acute
myocardial infarction [61,74].
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Responses to DNA damage are highly complex and present a multitude of potential targets
for therapeutic interventions aimed at selectively killing cells with dysregulated growth or
sparing tissues with limited regenerative capacity from harmful insults [75]. The robust
synthesis and turnover of poly (ADP-ribose) during the DNA damage response, catalyzed by
PARP-1 and PARG, represents a broad paradigm for interrogating many facets of DNA
repair, damage signaling, and programmed cell death through the use of small molecule
ligands. Our growing understanding of the structures and catalytic mechanisms of PARP-1
and PARG will guide the rational development of pharmacological agents that be invaluable
for examining the dynamic interplay of pathways that determine cell fate in normal and
diseased tissues.

Abbreviations
PAR

poly(ADP-ribose)

PARP

PAR polymerase

PARG

PAR glycohydrolase

MARG

mono-(ADP-ribose) glycohydrolase

PARylation

poly(ADP-ribosylation)
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Figure 1. The rise and fall of poly(ADP-ribose)

The ADP-ribose posttranslational modification regulates many fundamental aspects of
human biology. During the DNA damage response, there is an acute and transient burst of
poly(ADP-ribose) production and turnover that facilitates repair and contributes to important
cell fate signaling events.
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Figure 2. DNA damage response PARPs
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Three human PARP enzymes are catalytically activated through binding to DNA damage:
PARP-1, PARP-2, and PARP-3. The WGR domain and the HD region of the catalytic
domain are defining and unique features of the DNA damage-dependent PARPs. PARP-1
consists of multiple domains that assume an active conformation upon binding to DNA
damage. Zinc finger domains 1 and 3 (Zn1 and Zn3) interact with a DNA break and pack
against the WGR domain, which serves as an intermediary between the C-terminal catalytic
and N-terminal DNA binding domains, and allosterically couples damage detection to
catalytic activation.
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Figure 3. PARG structure and catalytic mechanism
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A. The catalytic domain of human poly (ADP-ribose) glycohydrolase PARG (residues
448-976) consists of a macro domain (green; residues 611-812) flanked by N-terminal and
C-terminal helical bundles (orange). The high affinity inhibitor adenosine diphosphate
hydroxymethyl(pyrrolidinediol) (ADP-HPD; blue) is bound in the active site cleft, flanked
by a β-hairpin structure termed the tyrosine clasp (red). Tyrosine 795 from the tyrosine clasp
interacts with the α-phosphate of ADP-HPD and ADP-ribose (see panel B). B. The active
site of PARG features a catalytic glutamate (Glu 756) and polar residues that engage the
ribose and pyrrolidine hydroxyl groups of ADP-HPD and two bound water molecules (red
spheres). The bound waters are positioned on either face of the carbon corresponding to the
anomeric position of a poly (ADP-ribose) substrate (yellow circle), where they could
function as the attacking nucleophile in a retaining (Wat A) or inverting (Wat B) mechanism
of hydrolysis. C. Proposed catalytic mechanisms for PARG [43,46] assign Glu 756 as the
catalytic acid that protonates the ADP-ribose leaving group, and as the catalytic base that
activates a water nucleophile for attack of the anomeric carbon of ribose”. An interaction
between the α-phosphorous and the 04″ of ribose (N of the pyrrolidine ring shown here)
may stabilize the carbenium intermediate to assist catalysis.
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